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Impact of clinical presentation and
presence of coronary sclerosis on long-term
outcome of patients with non-obstructive
coronary artery disease
Christine K. Kissel1,2* , Guanmin Chen3,4, Danielle A. Southern3,4, P. Diane Galbraith1, Todd J. Anderson1
and for the APPROACH investigators
Abstract
Background: Non-obstructive coronary artery disease (NOCAD) is a common finding on coronary angiography. Our
goal was to evaluate the long-term prognosis of NOCAD patients with stable angina (SA).
Methods: The study cohort consisted of 7478 NOCAD patients with normal EF (≥ 50%), and SA who underwent
coronary angiography between 1995 and 2012. We compared NOCAD patients (stenosis< 50%) with 10,906 patients
with stable obstructive CAD (≥ 50%). The primary endpoint was all-cause mortality. Secondary endpoints included
repeat angiography, progressive CAD, and PCI. A second comparison group consisted of 7344 patients with NOCAD
presenting with an ACS. Rates of all-cause mortality of NOCAD ACS patients were compared to NOCAD SA patients.
Results: Median follow-up time was 6.5 years. NOCAD patients had a lower risk of all-cause mortality compared to
CAD patients (HR CAD vs. NOCAD 1.33 (1.19–1.49); p < 0.001). This was driven by patients with normal coronary
arteries (HR CAD vs. normal 1.63 (1.36–1.94), p < 0.001), whereas patients with minimal disease (> 0% and < 50%)
were at similar risk as CAD patients (HR CAD vs. minimal 1.08 (0.99–1.29), p = 0.06). In NOCAD patients, the strongest
predictors of all-cause mortality were age and minimal disease. SA patients with NOCAD had low rates of repeat
angiography (7.3%), future CAD (2.3%) and PCI (1.7%). NOCAD ACS patients had a 41% increase in all-cause
mortality risk compared to NOCAD SA patients (HR 1.41 (1.25–1.6), p < 0.001).
Conclusions: This study underlines the importance of minimal CAD, as it is not a benign disease entity and
portends a similar risk as stable obstructive CAD.
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Background
Non-obstructive coronary artery disease (NOCAD) is a
common finding on diagnostic coronary angiograms with
rates of up to 50–60% in patients with stable angina (SA)
and of about 30% in certain population with acute coron-
ary syndromes (ACS) [1–4]. Symptomatic patients with
NOCAD have often been reassured of the innocuousness
of the results, and frequently no further preventive mea-
sures were taken [5, 6]. The etiology of symptoms in these
patients appears to be heterogeneous and prognosis was
often deemed favourable. Recently, the conception that
NOCAD is a benign disease has been challenged [3, 4, 6,
7]. Jespersen et al. showed a graded increase in major ad-
verse cardiovascular events (MACE) in patients with nor-
mal arteries, non-obstructive, and obstructive coronary
disease. These findings were confirmed by Maddox et al.
who demonstrated an increase of all-cause mortality and
MI rate from non-obstructive to obstructive CAD by
extent of vessel distribution in a cohort of mostly male
veterans presenting for an elective coronary angiogram
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[7]. One of the first study groups who followed NOCAD
patients systematically was the WISE study group
(Women’s Ischemia Syndrome Evaluation). WISE primar-
ily examined women, who were found to have cardiac syn-
drome X, i.e. chest pain of an ischemic origin and
NOCAD. The authors demonstrated a high rate of
all-cause mortality rate (18% in 10 years), and high rates
of repeat angiogram (19%) in women with NOCAD and
SA [3]. In contrast, the Swedish Coronary Angiography
and Angioplasty Registry (SCAAR) registry demonstrated
a low all-cause mortality of 0.3–0.4% in NOCAD patients
with SA at 2 years [2], hereby raising the question about
contemporary, long-term all-cause mortality in NOCAD.
Furthermore, it is well known that presentation with
an ACS with obstructive CAD portends an increased
mortality risk. Previous studies addressed ACS patients
with NOCAD, which is also termed myocardial infarc-
tion with non-obstructive coronary arteries (MINOCA),
but study size was either small or patients were followed
only in the short-term [8–12].
Our aim was therefore to evaluate prognosis and its
predictors in a large, contemporary population of pa-
tients of both sexes with NOCAD. We also sought to in-
vestigate whether presentation with an ACS leads to a
worse prognosis compared to stable NOCAD patients.
Methods
Data source and collection
Eligible subjects included all adults over the age of
18 years undergoing their first cardiac catheterization
between January 1, 1995 to March 31, 2012, registered
in the Alberta Provincial Project for Outcome Assess-
ment in Coronary Heart Disease (APPROACH©) data-
base [13]. APPROACH is a prospective cohort of all
adults undergoing cardiac catheterization in Alberta,
Canada. APPROACH contains detailed patient informa-
tion, as well as specifics on coronary anatomy and thera-
peutic interventions. Data were entered at time of
catheterization and are routinely enhanced by merging
the clinical registry data to administrative records.
Data collection included e.g. sociodemographic character-
istics, comorbidities and risk factors, disease specific vari-
ables (e.g. indication for procedure, angina status), and
medications at time of catheterization. Angiography results
including coronary anatomy, extent of coronary stenosis,
and LV ejection fraction (EF) were also recorded [13]. The
degree of stenosis was visually assessed by the angiographer
with no quantitative measurement. Subsequent angiogra-
phies and revascularization procedures are also collected.
APPROACH and this protocol were approved in ac-
cordance with the Declaration of Helsinki by the Institu-
tional Ethics Review Board of the University of Calgary.
Patients signed informed consent to allow data collection,
clinical follow-up, and anonymous data reporting.
Study population
Normal coronaries, minimal disease (i.e. coronary scler-
osis) and significant obstructive disease were defined as
0%, > 0 and < 50% and ≥ 50% luminal narrowing in any
epicardial coronary artery, respectively. The NOCAD co-
hort consisted of those with normal coronary arteries or
minimal disease. We identified patients with a normal
EF (≥50%) who presented with either SA or an ACS.
Stable angina (SA) was defined as Canadian Cardiovas-
cular Society (CCS) class 1, 2 or 3 angina with inclusion
of clinically stable patients with atypical chest pain. ACS
was defined as unstable angina or non–ST-elevation MI
or ST-elevation MI in accordance to universal myocar-
dial infarction criteria.
Patients with an EF below 50% or prior percutaneous
coronary intervention (PCI) or coronary artery bypass
grafting (CABG) were excluded, as well as patients with
significant valvular disease, or left main disease, or refer-
rals for pre- or post-transplant work-up, evaluation of
heart failure, congenital heart disease, or serious
arrhythmia. Patients with incomplete data were likewise
excluded. The rate of incomplete data was low (3.7%).
The main study group consisted of patients with
NOCAD (coronary stenosis < 50%) presenting with SA
(n = 7478). Comparison Group I contained patients with
significant CAD (≥ 50% stenosis) who presented with SA
(n = 10,906). Comparison Group II included patients
with NOCAD presenting with an ACS (n = 7344).
Outcomes
The primary end-point was all-cause mortality with the pri-
mary efficacy analysis consisting of a comparison between
CAD and NOCAD patients with SA. Follow-up all-cause
mortality was ascertained through semi-annual linkage to
the Alberta Bureau of Vital Statistics. The survival time
from the date of first catheterization was calculated using
the date of death. The survival time was censored if the pa-
tient was still alive on 31 March 2012. Secondary endpoints
were development of obstructive CAD (≥ 50% stenosis on
subsequent angiograms), repeat angiogram, and future PCI
in NOCAD patients. Any patient who had a second angio-
gram during the follow-up period was counted once as hav-
ing had a repeat angiogram.
Statistical methods
Summary statistics for categorical variables presented in-
clude counts and percentage, and for continuous variables
include mean and standard deviation. The difference for
categorical variables between NOCAD and CAD was tested
by Chi-square test; and the difference for continuous vari-
ables were evaluated by student’s t-test. Cox’s proportional
hazard regression model was used to compare all-cause
mortality between CAD and NOCAD. The crude hazard
ratio (HR) and adjusted HR with their 95% confidence
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intervals were estimated. In the multivariable-adjusted
model, we adjusted the HRs for age, diabetes mellitus
(DM), and hypertension. The analyses for Cox’s propor-
tional hazard regression model were stratified by the groups
of NOCAD and its subgroups of normal coronaries, and
minimal disease (> 0 and < 50%), as well as obstructive
CAD. We estimated HRs between NOCAD and CAD pa-
tients, stratified by coronary status, and between NOCAD
patients presenting with SA or an ACS.
Moreover, Cox’s proportional hazard regression
models were used to investigate predictors for all-cause
mortality among patients with NOCAD. Pre-specified
variables for the univariate Cox regression model in-
cluded age over 55 years, presence of DM, positive stress
test, abnormal baseline ECG, hypertension, or previous
or current smoking, as well as having undergone more
than two angiograms for the same condition.
Factors, which showed a significant association with
increased mortality in the univariate analysis, were en-
tered in the multivariate regression model using a step-
wise method. To explore the effect of sex, we included
this factor in our analyses, independently of the signifi-
cance level in the univariate model. We conducted these
analyses for NOCAD patients with SA. All statistical
analyses were performed using statistical software SAS
(Version 9.3, Institute Inc., Cary, NC).
Results
During the study period, there were 141,004 patients in the
APPROACH registry with 70.2% men and 29.8% women.
For reasons previously described, we excluded 92,126 pa-
tients, leaving a population of 48,878 subjects with normal
EF. Figure 1 shows that of the normal EF group, 7478 sub-
jects had NOCAD presenting with SA. In the NOCAD
subgroup, the percentage of women was substantially
higher than the total APPROACH population (48.5%).
NOCAD was found in 40.7% of all patients presenting with
SA, whereas the rate for NOCAD in patients presenting
with an ACS was 24.1% (Fig. 1). The median follow-up time
was 6.5 years, the maximum was 13.5 years.
Baseline characteristics of NOCAD population with SA
NOCAD patients were significantly younger, were more
likely to be female and had significantly lower rates of
cardiovascular risk factors compared to CAD patients. A
similar picture emerged when patients with normal cor-
onary arteries were compared to patients with minimal
disease (Additional file 1: Table S1). At the time of
catheterization, medication use was higher in the CAD
population (Table 1).
Comparison of all-cause mortality of NOCAD versus CAD
patients
The crude all-cause mortality at 10 years occurred in
5.3% and 9.8% of stable patients with NOCAD and
CAD, respectively (p < 0.001). SA patients with NOCAD
had a lower risk of all-cause mortality than patients with
CAD after adjustment for basic risk factors (Table 2).
However, when the NOCAD population was divided in
patients with completely normal coronary arteries and
Fig. 1 Flow diagram of patient population
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patients with minimal disease, the latter appeared to
have a similar risk as CAD patients (Table 2). Patients
with completely normal coronary arteries had a lower
risk compared to patients with CAD. The Kaplan Meier
survival curves between NOCAD (normal, minimal),
and obstructive CAD adjusted for age, hypertension, and
diabetes are depicted in Fig. 2.
When NOCAD patients presented with an ACS rather
than with SA, they had a 41% increase in mortality risk
(NOCAD ACS vs. SA HR 1.41 (1.25–1.6), p < 0.001).
Secondary endpoints in NOCAD SA population
Over a median of 6.5 years of follow up, the percentage of
subjects with a repeat catheterization was low (n = 543
(7.3%)). Simultaneously, progression to obstructive CAD
in patients with NOCAD was small (n = 170 (2.3%)), as
well as the necessity to perform a PCI (n = 128 (1.7%)).
Overall, patients with a NOCAD had significantly lower
rates of cardiac procedures than patients with stable
one-vessel CAD (p < 0.001).
Independent predictors of primary and secondary
endpoints
To determine independent predictors of all-cause mortal-
ity in the NOCAD population, we performed a multivari-
ate Cox regression analysis, including pre-specified
variables as described in the methods’ section. Age above
55 years was the strongest independent predictor of
all-cause death (Table 3). Subjects with minimal disease
compared with normal coronary arteries were at increased
Table 1 Comparison of Baseline Characteristics of Stable Angina Patients: NOCAD versus CAD
NOCAD (n = 7478) CAD
(n = 10,906)
p-value*
Age, mean years 58.8 ± 10.9 64.0 ± 10.2 < 0.001
Female (%) 3517 (47%) 2514 (23.1%) < 0.001
EF calculated (n = 2599) 64.9 ± 7.5 63.7 ± 12.6 < 0.001
Normal coronary arteries 49.4% N/A N/A
Cardiovascular risk factors:
Hypertension (%) 60.4 72.1 < 0.001
Dyslipidemia (%) 65.6 79.2 < 0.001
Diabetes mellitus (%) 16.8 26.6 < 0.001
Smoker- current/ previous (%) 52.5 61.6 0.04
Current smoker (%) 17.7 18.9 < 0.001
Positive family history (%) 29.6 29.1 0.47
Medications at time of cath:
Aspirin 5286/7159 (73.8%) 8940/10555 (84.7%) < 0.001
P2Y12 Inhibitor 480/6878 (7%) 1105/10078 (11.0%) < 0.001
Beta-blockers 3561/7060 (50.4%) 6626/10423 (63.6%) < 0.001
Statins 3285/6926 (47.4%) 6681/10048 (66.5%) < 0.001
Calcium channel blockers 1269/6911 (18.4%) 2343/10115 (23.2%) < 0.001
ACE-inhibitor 1957/6969 (28.1%) 3983/10429 (38.2%) < 0.001
Long acting nitrates 867/6862 (12.6%) 1716/ 10,043 (7.1%) < 0.001
Insulin 193/5760 (3.4%) 445/8442 (5.3%) < 0.001
*for comparison NOCAD vs. CAD
Table 2 All-cause mortality and adjusted hazard ratios for comparison of CAD patients with NOCAD patients
Age, DM, HTN- adjusted
Deaths
n
Total
n
10-year rate (%) HR (95% CI) p-value
NOCAD 398 7478 5.3 1.33 (1.19–1.49) < 0.001*
normal 132 3691 3.6 1.63 (1.36–1.94) < 0.001†
minimal 266 3787 7 1.08 (0.95–1.23) 0.06‡
CAD (> 50%) 1068 10,906 9.8 – –
*: CAD vs. NOCAD; †: CAD vs. normal; ‡: CAD vs. minimal
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risk of death, and this was higher than the risk associated
with the presence of diabetes or smoking (Table 3).
Table 4 shows that for the secondary endpoints of fu-
ture development of obstructive CAD, repeat angiogram,
and future PCI, presence of minimal CAD was the
strongest independent predictor in all of the three sub-
groups, followed by DM, and male sex.
Discussion
Our large, contemporary study of SA patients with
NOCAD and normal LV-function found several key
findings. Patients with NOCAD had favourable long-
term rates of repeat angiography, future CAD, and PCI.
Nevertheless, patients with minimal disease had a simi-
lar risk of all-cause mortality as patients with stable
CAD. Finally, NOCAD patients presenting with an ACS,
had a 41% increase in all-cause mortality compared with
those with a SA presentation.
We were able to demonstrate low rates of repeat angiog-
raphy for patients with NOCAD. Our rate of repeat
catheterization is in line with results reported by others [9,
14]. But this is in contrast to reports from the WISE study
cohort, which reported higher rates of repeat angiography of
18–34.5% [15, 16]. The WISE cohort had a high proportion
of persistently symptomatic women [16]. Data on persistence
of symptoms is unfortunately not available to us. We can
only speculate whether our lower rate of repeat
catheterization is due to lower rate of persistent symptoms,
or an increased awareness of physicians of cardiac syndrome
X, and microvascular angina. Further potential explanations
might be differences in national/regional practices.
We further showed that NOCAD patients presenting
with ACS are at increased risk for all-cause mortality. In
daily practice however, the finding of NOCAD on coron-
ary angiography is often regarded as insignificant, even
when patients present with an ACS. The cause of ACS
in NOCAD patients is often unclear, and a variety of eti-
ologies can account for the findings [12, 17]. It is also
well documented that a large number of plaque ruptures
occur at the site of non-obstructive lesions that lead to
thrombotic occlusion [18, 19]. Some of the ACS patients
likely had a plaque rupture but the thrombus was not
visible at time of cardiac catheterization anymore. Fur-
thermore, plaque erosion is a potential cause for ACS,
which might have been missed in some cases [20]. Since
we did not routinely perform intravascular ultrasound or
optical coherence tomography (OCT), we do not know
the percentage of patients with a plaque rupture or ero-
sion without obvious filling defect. Furthermore, it is
known that in symptomatic patients with NOCAD,
endothelial dysfunction can lead to signs and symptoms
of coronary ischemia and is associated with a worse
prognosis [9, 21–23]. We do not have any measures of
Table 3 Independent predictors for all-cause mortality in
NOCAD SA patients
Variables HR (95% CI) p-value
Minimal CAD vs. Normal 1.69 (1.35–2.12) < 0.001
Age≥ 55 years vs. Age < 55 years 3.34 (2.48–4.51) < 0.001
Diabetes mellitus vs. No diabetes 1.5 (1.16–1.94) 0.002
Normal ECG vs. Abnormal 0.67 (0.52–0.87) 0.002
Hypertension vs. No hypertension 1.23 (0.98–1.55) 0.08
Smoker vs. Non-smoker 1.53 (1.23–1.91) < 0.001
Men vs. Women 1.26 (1.01–1.56) 0.04
Fig. 2 Kaplan Meier curve of patients with stable angina and NOCAD (normal, minimal), and obstructive CAD adjusted for age, hypertension,
and diabetes
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endothelial function in this study. We can only speculate
that coronary endothelial dysfunction led to symptoms
and was possibly more pronounced in patients present-
ing with an ACS, which in turn led to a worse outcome.
On the other hand, myocarditis and Takotsubo cardio-
myopathy are also potential causes for an ACS- like
presentation in patients with NOCAD. Albeit Takotsubo
was first described in 1990 in a Japanese publication and
has gained worldwide recognition since [24], awareness
for Takotsubo was delayed in Western countries and it
could well be that some of the earlier inclusions in the
APPROACH cohort underdiagnosed Takotsubo. Taken
together, patients with NOCAD and ACS likely consti-
tute different etiologies [12, 17]. Given that this patient
cohort has a 41% increase in risk, a thorough work-up is
warranted to better define the etiology in the individual
patient, and to appropriately treat patients according to
etiology. In clinical reality, patients with an ACS and
NOCAD, and no obvious filling defect, or spasm, often
receive less secondary preventive measures [5, 17].
In regard to the increased all-cause mortality risk of pa-
tients with minimal disease, our data reinforces results
from contemporary studies done by coronary computed
tomography angiography (CCTA), which showed that pa-
tients with NOCAD had a similar mortality risk as pa-
tients with obstructive 1-vessel CAD [25]. Concomitantly,
the study confirms a graded increase in risk from normal
coronaries to non-obstructive disease to obstructive CAD
as reported by angiographic studies, as well as by CCTA
studies [4, 5, 15, 25–27]. Recently, Maddox et al. were able
to show a graded increase of all-cause mortality and MI
rate at 1 year from non-obstructive to obstructive CAD in
a large, mostly male, cohort of US veterans who presented
for an elective coronary angiogram [5]. Although we did
not divide the groups by extent of disease, we were able to
confirm an increase in all-cause mortality from normal to
coronary sclerosis to obstructive disease in an all-comer
population for a longer follow-up period. One of the most
important findings of our studies was that patients with
minimal disease had a similar HR for all-cause mortality
as patients with stable CAD. Minimal disease was an inde-
pendent predictor of similar strength as DM and smoking
in our study. This is in line with several other studies. Re-
cent meta-analyses also confirmed a poorer prognosis of
patients with minimal disease compared to patients with
normal arteries [28]. Furthermore, Lin et al. demonstrated
that the detection of NOCAD improves prediction of
mortality beyond conventional risk factor assessment [26].
Overall, data appears to accumulate that the finding of
NOCAD is not benign and should prompt consideration
of secondary prevention measures as used in subjects
with stable obstructive CAD. Large-scale studies are
warranted to determine the benefit of such measures.
Limitations
Some limitations apply to this study. Foremost, this was
not a randomized controlled trial but a population-based
registry study with all its ensued limitations of potential
confounding and unmeasured covariates. However, the
strength of the APPROACH registry is that it provides a
real-world scenario and it captures all deaths and revas-
cularization procedures within the province.
Of note is that APPROACH is a procedure-based regis-
try and not a clinical registry. We cannot exclude a diag-
nosis, angiogram and/or hospitalization referral bias.
However, based on information from an APPROACH
ACS registry, it is known that 73.9% of women and 85.1%
of men (p < 0.05) who present to our region with ACS
undergo catheterization. Furthermore, we used multivari-
able adjustment as strategy to account for baseline
differences between patients with NOCAD and CAD.
Nevertheless, residual confounding cannot be excluded.
One of the major limitations is that there is no data on the
cause of death or cardiovascular death in particular in the AP-
PROACH database. Rehospitalisation rates for ischemia or
heart failure, stroke, or quality of life measures are not known
for NOCAD patients. Those endpoints have been proven to
be of special importance in patients with NOCAD [4, 14, 16].
Nonetheless, data on the hard endpoint of all-cause mortality
is robust and of clinical significance. We are also lacking data
Table 4 Independent predictors for repeat angiogram, future PCI, and progression of CAD in NOCAD SA patients
Repeat angiogram
(n = 543)
Future PCI
(n = 128)
Future CAD
(n = 170)
Variables HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Minimal vs. normal 1.87 (1.53–2.29) < 0.001 3.78 (2.38–6.01) < 0.001 3.83 (2.59–5.66) < 0.001
Age≥ 55 years vs. age < 55 years 1.41 (1.14–1.75) 0.001 1.15 (0.76–1.75) 0.51 1.52 (1.05–2.2) 0.03
Diabetes mellitus vs. no diabetes 1.64 (1.28–2.1) < 0.001 3.3 (2.15–5.08) < 0.001 2.03 (1.34–3.07) 0.001
Normal ECG vs. abnormal 0.8 (0.63–1.01) 0.06 1.13 (0.73–1.75) 0.57 0.61 (0.39–0.94) 0.03
Hypertension vs. no hypertension 1.2 (0.98–1.47) 0.07 1.18 (0.78–1.78) 0.44 1 (0.71–1.4) 0.98
Smoker vs. non-smoker 1.15 (0.94–1.4) 0.18 1.05 (0.7–1.57) 0.82 1.42 (1–2.01) 0.05
Men vs. women 1.42 (1.17–1.74) < 0.001 2.33 (1.52–3.57) < 0.001 1.78 (1.25–2.52) 0.001
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on long-term medication use or risk factor control. During
the long follow-up period from 1995 to 2012, medical man-
agement of patients also might have changed. For instance,
high dose statin therapy became more common in the early
twenty-first century. Also, physicians might have been more
prone to use secondary preventive measures in NOCAD over
time. A further concern is that it can be difficult to discern
normal coronaries from NOCAD. Intravascular ultrasound
data, or OCT would have been beneficial but is rarely used
for diagnostic angiograms under the specified conditions.
Furthermore, grade of stenosis was not assessed in a core lab
by quantitative coronary analysis. Therefore, under- or
overestimation of stenosis grade cannot be ruled out. In spite
of these limitations, our study represents a real-world scenario
and is similar to other large-scale registries.
In regard to the study design, one of the main draw-
backs is the lack of an asymptomatic, normal control.
However, previous studies have shown that there is a
graded increase from asymptomatic controls to symp-
tomatic with normal coronary arteries [4].
Conclusion
In conclusion, stable patients with NOCAD have low rates
of repeat angiography, future CAD, and PCI. This is re-
assuring when dealing with and treating these patients.
However, subjects with minimal disease should be consid-
ered at similar risk as patients with stable, obstructive
CAD, which might argue for more aggressive risk factor
control in these patients. Also, NOCAD patients present-
ing with an ACS have a 41% increase in risk for all-cause
mortality which might warrant more intensive diagnostic
evaluation, treatment, and follow-up.
Additional file
Additional file 1: Table S1. Comparison of Baseline Characteristics of
Stable Angina Patients with NOCAD: normal coronaries vs. minimal disease.
(DOCX 15 kb)
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